Clinical Trial: Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment

U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06848894) titled 'Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment' on Feb. 20.

Brief Summary: This study aims to explore the efficacy and safety of Human Urinary Kallidinogenase for acute ischemic stroke patients receiving intravenous thrombolysis and/or endovascular treatment.

Study Start Date: Feb., 2025

Study Type: INTERVENTIONAL

Condition: Acute Ischemic Stroke

Intervention: DRUG: Human urinary kallidinogenase (HUK)

HUK (0.15 PNA) and sodium chloride injection (100ml), once per day

DRUG: Placebo

placebo (0 PNA) and sodium chloride injection (100ml), once per day

Rec...